Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
color
DRUG
2 trials
Sponsors
Alkeus Pharmaceuticals Inc.
, Rochester Institute of Technology
Conditions
L- and M-cone Modulation Only
L- and S-cone Modulation Only
M and S-cone Modulation Only
Monochromatic
Stargardt Disease (STGD1)
Phase 3
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
Not yet recruiting
CTIS2026-525296-60-00
Alkeus Pharmaceuticals Inc.
Stargardt Disease (STGD1)
Target: 43
Updated: 2026-08-21
Unknown Phase
Evaluating How Well Different Types of Light-sensitive Cells in the Eye Contribute to Its Focusing Ability
Recruiting
NCT07691463
Rochester Institute of Technology
Monochromatic, L- and S-cone Modulation Only, L- and M-cone Modulation Only +1
Start: 2026-07-02
End: 2026-12-15
Target: 20
Updated: 2026-07-17